Table 5.
Characteristic Name | Crude RR Discontinuation Due to Side Effects, RR (95% CI) | Adjusted RR Discontinuation Due to Side Effects, RR (95% CI) | |
---|---|---|---|
Age | Less than 18 years | 0.88 (0.31 - 2.47) | 0.80 (0.29 - 2.23) |
Age | 18-39 years | 1.00 | 1.00 |
Age | 40-54 years | 1.81 (1.00 - 3.28) | 1.69 (0.90 - 3.18) |
Age | 55-64 years | 3.35 (1.63 - 6.88) | 3.25 (1.54 - 6.88) |
Age | 65 years or more | 4.43 (2.09 - 9.36) | 5.66 (2.14 - 14.98) |
Type of inflammation | Anterior | 1.00 | 1.00 |
Type of inflammation | Intermediate | 0.39 (0.18 - 0.83) | 0.49 (0.22 - 1.09) |
Type of inflammation | Posterior/Panuveitis | 0.68 (0.38 - 1.21) | 0.73 (0.38 - 1.42) |
Type of inflammation | Scleritis | 2.30 (0.93 - 5.67) | 2.01 (0.55 - 7.40) |
Type of inflammation | Mucous Membrane Pemphigoid | 0.90 (0.14 - 5.75) | 0.41 (0.05 - 3.36) |
Dosage | 150 mg/day or less | 1.00 | 1.00 |
Dosage | 151-250 mg/day | 0.34 (0.17 - 0.69) | 0.34 (0.16 - 0.73) |
Dosage | 251-350 mg/day | 0.53 (0.27 - 1.04) | 0.59 (0.29 - 1.20) |
Dosage | 351 mg/day or more | 0.55 (0.30 - 1.03) | 0.69 (0.35 - 1.34) |
Systemic (extraocular) autoimmune disease | Yes | 0.98 (0.60 - 1.62) | 0.76 (0.42 - 1.39) |
RR=Relative risk
CI=Confidence interval